Last reviewed · How we verify
NCT06734858
Pivotal Trial of SAT-014 for Trauma and Stressor-Related Disorder Symptoms
NA trial testing SAT014 in Post-traumatic Stress Disorder in 110 participants. Completed in 29 May 2025.
29 May 2025
Quick facts
| Lead sponsor | S-Alpha Therapeutics, Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 110 |
| Start date | 9 December 2024 |
| Primary completion | 29 May 2025 |
| Estimated completion | 29 May 2025 |
| Sites | 5 locations across South Korea |
Drugs / interventions tested
- SAT014
- Control
Conditions studied
- Post-traumatic Stress Disorder — all drugs for Post-traumatic Stress Disorder →
- Adjustment Disorders — all drugs for Adjustment Disorders →
Sponsor
S-Alpha Therapeutics, Inc.
Who can join
19 and older, any sex, with Post-traumatic Stress Disorder or Adjustment Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to evaluate the efficacy of SAt-014, a software as a medical device (SaMD), in alleviating symptoms of trauma and stressor-related disorders in patients with post-traumatic stress disorder (PTSD) or adjustment disorder (AD), compared to standard treatment, and to assess its safety for regulatory approval by the Ministry of Food and Drug Safety (MFDS).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06734858
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Post-traumatic Stress Disorder
Currently open trials in the same condition.
- NCT06943404 — BXCL501 After Stress to Increase Recovery Success · Phase 2 · recruiting
- NCT06477796 — Improving Sleep in Veterans With the Polytrauma Clinical Triad · NA · recruiting
- NCT06538246 — Adaptive Coping Skills Training to Improve Psychological Distress Among Cardiorespiratory Failure Survivors · NA · recruiting
- NCT06592677 — Early Support After Exposure to Trauma · NA · recruiting
- NCT05927324 — Clinician-Assisted Videofeedback Exposure-Approach Therapy (CAVEAT) Trial · NA · recruiting
Other S-Alpha Therapeutics, Inc. trials
Trials by the same sponsor.
- NCT06742268 — Extension Study on Safety and Rebound Effect of SAT-001 for Myopia in Children · recruiting
- NCT06729723 — Exploratory Study on the Effect of SAT-001 on Choroidal Thickness in Pediatric Myopia Patients · NA · completed
- NCT06439407 — Clinical Trial to Preliminarily Assess the Safety and Feasibility of SAT-014, a Software for Alleviating Symptoms of Tra · NA · completed
- NCT06344572 — Pivotal Study of SAT-001 in Treatment of Pediatric Patient With Myopia · NA · recruiting
- NCT06476197 — Exploratory Trial of SAT-003 in Cancer Cachexia Patients With Discontinued Chemotherapy · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06734858 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by S-Alpha Therapeutics, Inc.
- Last refreshed: 5 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06734858.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing